Global donors pledge over US$777 million to defeat neglected tropical diseases and improve the lives of 1.6 billion people at the Reaching the Last Mile Forum at COP28
Global donors at the 2023 Reaching the Last Mile Forum today pledged a collective US$777.2 million to help control, eliminate, and eradicate neglected tropical diseases (NTDs), in a landmark push to accelerate progress towards achieving the goals outlined in the World Health Organization’s 2030 roadmap on NTDs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231203773888/en/
Uniting efforts with NTD-endemic countries, donors answered the urgent call to step up the fight against NTDs in the face of climate change, and to work together to improve the lives of the 1.6 billion people worldwide affected by these devastating yet preventable diseases.
The pledging event was hosted by Reaching the Last Mile (RLM), the global health initiative driven by the philanthropy of His Highness Sheikh Mohamed Bin Zayed Al Nahyan, President of the UAE, in partnership with the Bill & Melinda Gates Foundation. The forum took place on the first ever Health Day during the United Nations Climate Change Conference (COP28).
His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs, UAE, was joined by world leaders including H.E. Samia Suluhu Hassan, President of Tanzania; and H.E. Dr Austin Demby, Minister of Health and Sanitation, Sierra Leone, in a demonstration of endemic country leadership against NTDs.
Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation, and His Highness Sheikh Theyab bin Mohamed Al Nahyan, Chairman of the Office of Development Affairs at the UAE’s Presidential Court, which oversees Reaching the Last Mile, were also in attendance, alongside ministers and global health leaders.
His Highness Sheikh Abdullah bin Zayed Al Nahyan stated: “The UAE is proud to host this pivotal conference and expresses gratitude to all those who have seized the opportunity to renew their commitment to end neglected tropical diseases. Today’s demonstration of global solidarity reflects a shared determination to deliver a better and more dignified future for all. Incredible progress over the last two decades has proved that a world free of NTDs is an achievable goal. We warmly thank governments, donors, and partners for standing with us as we strive to achieve it.”
Reaching the Last Mile joined with the Gates Foundation and global partners to announce a milestone expansion of the Reaching the Last Mile Fund (RLMF) from $100m to $500m. The expansion will increase the reach of the fund from seven countries to 39 across Africa and Yemen, with the audacious goal of eliminating two NTDs, lymphatic filariasis and onchocerciasis (river blindness), from the continent of Africa.
The funding builds on the pioneering success of the RLMF, which launched in 2017 as a 10-year, multi-donor fund, to establish a model for eliminating the two diseases in sub-Saharan Africa.
His Highness Sheikh Theyab bin Mohamed Al Nahyan said: “Today we reaffirm our pledge to eliminate these diseases of poverty, and save and improve lives worldwide. Climate change is already affecting the patterns of infectious diseases and risking the tremendous gains countries have made to date.
“With endemic countries leading the way, the Reaching the Last Mile Fund represents a historic opportunity to free communities across Africa from the threat of two NTDs, and in partnership unlock the potential for a healthier world.”
“Climate change is inextricably linked to poverty and diseases affecting millions,” said Bill Gates, Co-chair of the Bill & Melinda Gates Foundation. “That is why funding for lifesaving healthcare is critical and why we’re joining global partners to build on the tremendous progress of the Reaching the Last Mile Fund to date, and accelerate the elimination of LF and river blindness across Africa and beyond.”
Reaching the Last Mile’s new $100m commitment, matching the Gates Foundation’s $100m commitment, represents a five-fold increase over the contributions made, respectively, to the fund at its launch.
Further contributions from country and donor partners including Sierra Leone, the Carter Center, Sightsavers, the Children’s Investment Foundation Fund (CIFF), The Helmsley Charitable Trust, the END Fund, and Abu Dhabi National Insurance Company will see RLMF significantly broaden its scope, with the aim of ensuring over 350 million people no longer require treatment for these diseases by 2030.
H.E. Julius Maada Bio, President of Sierra Leone, said: “There is clarity of vision as well as growing demand and energy in Africa to see the continent free of NTDs. Political commitment has been sustained and energised through the Kigali Declaration, and through the Continental Framework and Common Africa Position on NTDs, which Sierra Leone is proud to have endorsed. That is why Sierra Leone is proud to pledge towards an Africa free of river blindness and lymphatic filariasis. Neglected tropical diseases cause suffering to millions, and we simply cannot afford to neglect them any longer.”
H.E. Samia Suluhu Hassan, President of Tanzania, said: "I am immensely proud to have been at the centre of the launch of this ambitious vision of an Africa free of river blindness and lymphatic filariasis. Tanzania commits to increase domestic contribution for combating NTDs but also counts on continued support from development partners in this endeavor.
"While gaps in global funding for NTDs remain, this initiative signifies a crucial step forward in enhancing the health and quality of life not just for Tanzanians, but for all who live on the African continent. Together, we can end these terrible diseases, forging a path to a healthier and brighter future for us all."
Over five years the RLMF has provided over 100 million treatments, trained 1.3 million health workers, and established nine laboratories to support NTD surveillance and testing. The fund also played a critical role in interrupting the transmission of river blindness in Niger, an achievement once thought to be scientifically impossible in Africa, and has supported Senegal in nearing this milestone.
The wider pledging moment saw new, multimillion-dollar commitments made by organizations including the Anesvad Foundation, CIFF, USAID, Global Health EDCTP3, UBS Optimus Foundation, NALA Foundation, Evidence Action, Helen Keller Intl, and the Fred Hollows Foundation, in addition to the governments of Germany and Belgium.
These pledges will help close the funding gap needed to expedite progress towards the WHO roadmap targets which call for at least 100 countries to have eliminated at least one NTD by 2030, and to reduce by 90% the number of people requiring treatment for NTDs.
To date, 50 countries have eliminated at least one NTD and 600 million people no longer require treatment. Cases of some diseases that have plagued communities for centuries, such as Guinea worm disease and sleeping sickness, are at an all-time low.
However, climate change is affecting the reach and prevalence of infectious diseases like NTDs, threatening to erase elimination gains and stall future progress.
The commitments will help finance essential programs and treatments, support new research and innovations, and strengthen frontline health systems and workforces, among other investments.
Dr Tedros Adhanom Ghebreyesus, Director General of the World Health Organization, said: "In light of the pledges made today at the 2023 Reaching the Last Mile Forum, I would like to express my profound gratitude to the global community, especially the pivotal leadership role of the United Arab Emirates, led by His Highness Sheikh Mohamed bin Zayed Al Nahyan.
“This commitment is a significant stride towards eradicating, eliminating, and controlling NTDs, aligning seamlessly with the 2021- 2030 NTD road map. The collaborative efforts of countries and global donors exemplify an unwavering dedication to improving the lives of the 1.6 billion people affected by these diseases. This partnership, especially in the face of challenges posed by climate change, represents a beacon of hope and a testament to what can be achieved through united global action"
The 2023 Reaching the Last Mile Forum convened more than 450 government ministers, global health and development experts, philanthropists, and civil society leaders to galvanize concrete commitments towards mitigating the effects of the climate crisis on human health.
About Reaching the Last Mile
Reaching the Last Mile (RLM) is a portfolio of global health programs, investments, and initiatives working towards disease elimination that is driven by the philanthropy of His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE. Through its partnerships and programs, RLM provides treatment and preventative care in communities that lack access to quality health services, with a focus on last-mile disease elimination.
RLM’s mission represents His Highness’s dedication to ending preventable diseases that affect the world’s most vulnerable communities, and to helping millions of children and adults live healthy, dignified lives.
https://www.reachingthelastmile.com
About the Bill & Melinda Gates Foundation
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of co-chairs Bill Gates and Melinda French Gates and the board of trustees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231203773888/en/
Contact information
Reaching the Last Mile media contacts:
Simone Elviss, GCI Health
Simone.elviss@gcihealth.com
+971 (0) 50 614 9383
Hilary Keno, GCI Health
hilary.keno@gcihealth.com
+1 847 338 0949
Bill & Melinda Gates Foundation media contact:
media@gatesfoundation.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease31.8.2024 17:00:00 CEST | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) study programme, at the European Society of Cardiology (ESC) Congress 2024. Gender inequalities in CV disease treatment and LDL-C goal attainment Raised low-density lipoprotein cholesterol (LDL-C) is a key modifiable contributor to risk of cardiovascular major events. It has been shown that for every 1 mmol/L reduction in LDL-C, there is a 22% reduction in major cardiovascular events after 1 year.7,8 Female patients in Europe who are at high or very high CV risk were undertreated and less achieved guideline-recomm
Suzano completes purchase of 15% stake in Lenzing AG31.8.2024 00:40:00 CEST | Press release
Suzano, the world's largest pulp producer, today announces the completion of its acquisition of a 15% stake in Lenzing AG, the Vienna-listed leading global supplier of sustainable premium cellulosic fibres for the textile and non-wovens industry, from B&C Group. As announced in June this year, the transaction value is EUR 230 million (or EUR 39.70 per share). The agreement was subject to regulatory approval, which was granted without restrictions. The long-term partnership between Suzano and B&C Group establishes that Suzano has the right to hold two seats on Lenzing’s Board and the option to acquire an additional 15% stake from B&C Group until the end of 2028. Following the sale of the 15% stake, B&C Group now holds 37.25% of Lenzing’s share capital. Lenzing is a leading global supplier of premium wood-based cellulosic fibers (lyocell, modal, and viscose) for the production of clothing, home textiles, hygiene products, and non-woven materials. Beto Abreu, CEO of Suzano, said: “Lenzing
Ant International Collaborates with Brazilian Partners to Drive Financial Inclusion with Innovative Credit Tech Solutions30.8.2024 20:46:00 CEST | Press release
Ant International, a digital payment and financial technology leader, today announced its strategic initiative to provide AI-driven credit technology solutions designed to empower local partners and advance financial inclusions in Brazil. As a major milestone, Ant International has formed a strategic partnership with Dock, a leader in payments and banking technology in Latin America. This collaboration aims to enhance the credit management capability and infrastructure efficiency for Dock’s clients, which include financial institutions, retailers, fintech start-ups, etc. The shared vision is to make credit services more inclusive for market segments that are currently insufficiently served, such as micro, small and medium-sized enterprises (MSMEs). In the initial phase of the collaboration, Ant International’s AI-driven credit tech solutions, including an automated and intelligent risk management engine, will be explored for integration into Dock One platform. This initiative aims to s
Wipro Appoints Srikumar Rao as Global Head of Its Engineering Edge Business Line30.8.2024 16:20:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Srikumar Rao as Global Head of its Engineering Edge Business Line, effective from October 5, 2024. Srikumar succeeds Harmeet Chauhan, who is stepping down to pursue opportunities outside the organization. Srikumar will report to Srini Pallia. Srikumar has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Chief Operating Officer (COO) of Wipro Engineering Edge (WEE) and Global Practice Head of Embedded Systems. His work has spanned several markets, selling and delivering specialized Engineering, Research, and Development (ER&D) services to Software & Internet, Semiconductor, Automotive, Manufacturing, and Communications clients. In his new role, Srikumar will continue to scale and strengthen Wipro’s engineering prowess. He will also be responsible for defining the vision
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress30.8.2024 12:00:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously published in TheNew England Journal of Medicine. As previously reported, the HELIOS-B study met all 10 of its primary and secondary endpoints, across both the overall and monotherapy populations, with statistical significance. Enrolled patients were predominantly New York Heart Association (NYHA) Class I or II with wild-type disease and had been diagnosed by non-invasive methods, with substantial concurrent treatment with available standard of care treatments such as tafamidis and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom